Lopatina Tatiana, Favaro Enrica, Danilova Ludmila, Fertig Elana J, Favorov Alexander V, Kagohara Luciane T, Martone Tiziana, Bussolati Benedetta, Romagnoli Renato, Albera Roberto, Pecorari Giancarlo, Brizzi Maria Felice, Camussi Giovanni, Gaykalova Daria A
Department of Medical Sciences, University of Turin, Turin, Italy.
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Cell Dev Biol. 2020 Sep 9;8:698. doi: 10.3389/fcell.2020.00698. eCollection 2020.
Head and neck squamous cell carcinoma (HNSCC) has a high recurrence and metastatic rate with an unknown mechanism of cancer spread. Tumor inflammation is the most critical processes of cancer onset, growth, and metastasis. We hypothesize that the release of extracellular vesicles (EVs) by tumor endothelial cells (TECs) induce reprogramming of immune cells as well as stromal cells to create an immunosuppressive microenvironment that favor tumor spread. We call this mechanism as non-metastatic contagious carcinogenesis. Extracellular vesicles were collected from primary HNSCC-derived endothelial cells (TEC-EV) and were used for stimulation of peripheral blood mononuclear cells (PBMCs) and primary adipose mesenchymal stem cells (ASCs). Regulation of ASC gene expression was investigated by RNA sequencing and protein array. PBMC, stimulated with TEC-EV, were analyzed by enzyme-linked immunosorbent assay and fluorescence-activated cell sorting. We validated the effects of TEC-EV on ASCs or PBMC by measuring invasion, adhesion, and proliferation. We found and confirmed that TEC-EV were able to change ASC inflammatory gene expression signature within 24-48 h. TEC-EV were also able to enhance the secretion of TGF-β1 and IL-10 by PBMC and to increase T regulatory cell (Treg) expansion. TEC-EV carry specific proteins and RNAs that are responsible for Treg differentiation and immune suppression. ASCs and PBMC, treated with TEC-EV, enhanced proliferation, adhesion of tumor cells, and their invasion. These data indicate that TEC-EV exhibit a mechanism of non-metastatic contagious carcinogenesis that regulates tumor microenvironment and reprograms immune cells to sustain tumor growth and progression.
头颈部鳞状细胞癌(HNSCC)具有较高的复发和转移率,其癌症扩散机制尚不清楚。肿瘤炎症是癌症发生、生长和转移的最关键过程。我们假设肿瘤内皮细胞(TECs)释放的细胞外囊泡(EVs)诱导免疫细胞以及基质细胞重编程,以创建有利于肿瘤扩散的免疫抑制微环境。我们将这种机制称为非转移性传染性致癌作用。从原发性HNSCC来源的内皮细胞(TEC-EV)中收集细胞外囊泡,并用于刺激外周血单核细胞(PBMCs)和原代脂肪间充质干细胞(ASCs)。通过RNA测序和蛋白质阵列研究ASC基因表达的调节。用酶联免疫吸附测定和荧光激活细胞分选分析用TEC-EV刺激的PBMC。我们通过测量侵袭、粘附和增殖来验证TEC-EV对ASCs或PBMC的作用。我们发现并证实TEC-EV能够在24-48小时内改变ASC炎症基因表达特征。TEC-EV还能够增强PBMC分泌TGF-β1和IL-10,并增加调节性T细胞(Treg)的扩增。TEC-EV携带负责Treg分化和免疫抑制的特定蛋白质和RNA。用TEC-EV处理的ASCs和PBMC增强了肿瘤细胞的增殖、粘附及其侵袭。这些数据表明,TEC-EV表现出一种非转移性传染性致癌作用机制,可调节肿瘤微环境并使免疫细胞重编程,以维持肿瘤生长和进展。